OBSAH

EDITORIAL ............................................................................................................................................. 1

OBSAH ................................................................................................................................................... 2

PROGRAM ............................................................................................................................................. 4

ODBORNÁ SYMPOZIA ........................................................................................................................ 10

Sympozium společnosti pro biologickou psychiatrii – emoční dysregulace napříč
psychickými poruchami ......................................................................................................................... 10

Limity a možnosti léčby antipsychotiky a neurostimulačními metodami ................................................12

Neprávem opomíjený a obávaný klozapin .............................................................................................12

Neinvazivní mozková stimulace (NIBS) napříč neuropsychiatrií – od výzkumu
ke klinické praxi ......................................................................................................................................13

Sympózium Psychofarmakologickej sekcie SPsS ..................................................................................14

Mikrobiom a možnosti jeho interakce s psychofarmaky .........................................................................16

Novinky v léčbě poruch příjmu potravy ...................................................................................................17

Ketaminem asistované psychoterapie (KAP) v léčbě celého neurotického spektra ..............................18

Nová vodítka psychiatrické společnosti ČLS JEP pro léčbu deprese ....................................................20

Intenzivní péče v psychiatrii ....................................................................................................................21

Psychedelika, problémové děti psychofarmakologie V: Stále problémové,
`nebo budoucnost? ................................................................................................................................22

Gerontopsychiatrie .................................................................................................................................23

Znepokojivé trendy v psychofarmakologii u dětí a adolescentů: Od nešťastné
psychopatologie k medicinalizaci ...........................................................................................................24

Děti, jejichž matky užívaly v těhotenství psychofarmaka: Medikovat, či nemedikovat
těhotné? ................................................................................................................................................ 25

Nové pokroky v oblasti VR terapie (terapie virtuální realitou): Ohlédnutí
za konferencí ICDVRAT 2024 ............................................................................................................... 26

Farmakodetektivky 2 ............................................................................................................................28

Neuropsychiatrické aspekty digitálních závislostí ................................................................................29

Psychedelika, problémové děti psychofarmakologie – neurobiologické okénko ..................................30

Inovace a výzvy v léčbě sexuálních dysfunkcí: od robotů po farmakologické přístupy ........................32

NOVÝ VÝZKUM ................................................................................................................................... 33

Zvýšenie endokanabinoidnej signalizácie ako cieľ pre farmakoterapiu
úzkostnýcha kognitívnych porúch ....................................................................................................... 33

Nárůst sérových hladin olanzapinu vlivem akutního zánětu ................................................................33

Vliv CB1 antagonisty / inverzního agonisty AM251 na metabolickou aktivitu P450:
`In vitro studie ..................................................................................................................................... 34

Vybrané génové varianty a odpoveď na liečbu escitalopramom u pacientov s diagnózou
depresívnej poruchy ........................................................................................................................... 34

Vztah mezi sérovou koncentrací 25(OH) vitaminu D, verbální pamětí a objemem
hipokampální šedé hmoty u pacientů s první epizodou schizofrenie ................................................. 34

Pravděpodobnostní kvantifikace trendu vlasového kortisolu pro dlouhodobé
monitorování terapie .......................................................................................................................... 35

Dynamika frontálního EEG jako indikátor odpovědi na antidepresivní léčbu:
Retrospektivní analýza pomocí Hurstova exponentu u pacientů s depresivní poruchou .................. 35

Medikační trajektorie antipsychotik a váhový přírůstek u prvotně hospitalizovaných
pacientů s první epizodou psychotického onemocnění ..................................................................... 36

VÝVĚSKOVÁ SDĚLENÍ .....................................................................................................................37

Preklinická P1–P11.................................................................................................................................37

Klinická K1–K16 .....................................................................................................................................41

WORKSHOPY ....................................................................................................................................... 49

Pohádky 1000+1 noci: interaktivně pojaté kazuistické střípky psychedelických ponorů
do nevědomého materiálu z více než tisíce ketaminových procesů na Klinice Psyon ...........................49

Algoritmus podávání off-label ketaminu v psychiatrii ................................................................................ 49

Práce s přepisem v imaginaci u transgeneračního traumatu .................................................................... 49

Deeskalace agitovaného pacienta ............................................................................................................ 50

Léčba závažných příznaků vybraných duševních poruch – EBM, umění, nebo magie?........................... 50

Farmakologická léčba ADHD u dospělých ................................................................................................ 50

REJSTŘÍK ................................................................................................................................................ 51

CONTENTS

EDITORIAL ................................................................................................................................................. 1

CONTENTS ................................................................................................................................................ 2

PROGRAM ................................................................................................................................................. 4

SCIENTIFIC SYMPOSIA ...........................................................................................................................10

Society for Biological Psychiatry Symposium– emotional dysregulation
acrosspsychiatric disorders ........................................................................................................................10

Limits and possibilities of treatment with antipsychotics and neurostimulation methods ......................... 12

Unjustly neglected and feared clozapine .................................................................................................. 12

Non-invasive brain stimulation (NIBS) across neuropsychiatry – from research
to clinical practice ......................................................................................................................................13

Symposium of the Psychopharmacological Section of the Slovak Psychiatric Society ............................ 14

The microbiome and its potential interactions with psychopharmacs ....................................................... 16

News in the treatment of eating disorders ................................................................................................. 17

Ketamine-assisted psychotherapy (KAP) in the treatment of the entire neurotic spectrum ...................... 18

New guidelines of Czech Psychiatric Society for treatment of depression ............................................... 20

Psychiatric intensive care ......................................................................................................................... 21

Psychedelics problem children of psychopharmacology V: Still problematic, or the future?..................... 22

Gerontopsychiatry .................................................................................................................................... 23

Disturbing Trends in Psychopharmacology in Children and Adolescents: From
unfortunate psychopathology to medicalization ....................................................................................... 24

Children whose mothers took psychopharmaceuticals during pregnancy: To medicate,
or not to medicate pregnant women? ....................................................................................................... 25

New advances in VR (virtual reality) therapy: A look back at the ICDVRAT 2024 conference ................. 26

Psychopharmacs detective stories 2nd .................................................................................................... 28

Neuropsychiatric aspects of digital addictions ......................................................................................... 29

Psychedelics, problem children of the psychopharmacology – neurobiological window ......................... 30

Innovations and challenges in the treatment of sexual dysfunctions: From robots
to pharmacological approaches ............................................................................................................... 32

NEW RESEARCH ................................................................................................................................... 33

Enhancement of endocannabinoid signaling as a target for pharmacotherapy
of anxiety and cognitive disorders ............................................................................................................ 33

Increase in serum olanzapine levels in acute inflammation ..................................................................... 33

Effect of the CB1 antagonist / inverse agonist AM251 on P450 metabolic activity:
An in vitro study ........................................................................................................................................ 34

Selected gene variants and escitalopram treatment response in patients
with depressive disorder ........................................................................................................................... 34

A relationship between 25(OH) vitamin D serum level, verbal memory and hippocampal
gray matter volume in first episode schizophrenia patients ...................................................................... 34

Probabilistic quantification of hair cortisol trend for long-term therapy monitoring ................................... 35

Frontal eeg dynamics as indicators of antidepressant response:
A Hurst exponent-based retrospective analysis in major depression disorder ......................................... 35

Trajectories of daily antipsychotic use and weight gain in people hospitalized
for first episode of psychosis .................................................................................................................... 36

POSTERS ................................................................................................................................................ 37

Preclinical P1–P11 ...................................................................................................................................37

Clinical K1–K16 .................................................................................................................. .................... 41

WORKSHOPS ......................................................................................................................................... 49

Tales of 1000+1 nights: interactively conceived casuistic shards of psychedelic dives
into unconscious material from over a thousand of ketamine processes at the Psyon Clinic .................. 49

Algoritm for off-label use of ketamine in psychiatry................................................................................... 49

Working with imagery rescripting in transgenerational trauma ................................................................ 49

Deescalation of agitated patient .............................................................................................................. 50

Treatment of severe symptoms of selected mental disorders – EBM, art, or magic? ............................. 50

Pharmacological treatment of ADHD in adults ........................................................................................ 50

INDEX ..................................................................................................................................................... 51